Обзоры (стр. 5 )

43.        Boulton TG, Nye SH, Robbins DJ, Ip NY, Radzlejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65:4:663—675. http://doi. org/10.1016/0092-8674(91)90098-J

44.        Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Darlene D. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med. 2008;14:264—275. doi:10.2119 / 2007-00101.Yu

45.        Schlessinger J. Cell signaling by receptor tyrosine kinases A large group of genes in all eukaryotes encode for. 2000;103:2:211—225.

46.        Yoon S, Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:1:21—44. http://doi. org/10.1080/02699050500284218

47.        Nierth-Simpson EN, Martin MM, Chiang T-C, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17/J-estradiol signaling: Implications for proliferation. Endocrinology. 2009;150:5:2436—2445. https://doi. org/10.1210/en.2008-0224

48.        Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, Hartzstark Z, Hannah B-B. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod. 2004;19:9:1957—1967. http://doi. org/10.1093/humrep/deh355

49.        Shushan A, Hannah B-B, Eyal M, Neri L, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril. 2007;87:1:127—135. http://doi. org/10.1016/j. fertnstert.2006.05.056

50.        levers H, Nusse R. Wnt/в-catenin signaling and disease. Cell. 2012;149:6:1192—1205. https://doi. org/10.1016/j. cell.2012.05.012

51.        Tanwar PS, Lee H-J, Zhang LH, Zukerberg LR, Taketo MM, Rueda BR, Teixeira JM. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod. 2009;81:3:545—552. https://doi. org/10.1095/biolreprod.108.075648

52.        Ono M, Yin P, Navarro A, Moravek MB, Coon JS, Druschitz SA, Serna VA, Qiang W, Brooks DC, Malpani SS, Ma J, Ercan CM, Mittal N, Monsivais D, Dyson MT, Yemelyanov A, Maruyama T, Chakravarti D, Kim JJ, Kurita T, Gottardi C, Bulun SE. Paracrine activation of WNT/в-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci. U. S. A. 2013;110:42:17053—17058. https://doi. org/10.1073/pnas.1313650110

53.        McWilliams M, Chennathukuzhi VM. Recent Advances in Uterine Fibroid Etiology. Semin Reprod Med. 2017;35:2:181—189. http://doi. org/10.1055/s-0037-1599090

54.        Peng L, Yong W, Yulong H, Anran W, Guizhi S, Masashi M, Peng L, Eva H, Khush M, Jian-Jun W. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil. Steril. 2009;91:6:2664—2675. http:// doi. org/10.1016/j. fertnstert.2007.10.083

55.        Burroughs KD, Howe SR, Okubo Y, Fuchs-Young R, LeRoith D, Walker CL. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol. 2002;172:1:83—93. http://doi. org/10.1677/joe.0.1720083

56.        Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod. 2005;11:6:441—450. http:// doi. org/10.1093/molehr/gah174

57.        Chen HX, Sharon E. IGF-1R as an anti-cancer target-trials and tribulation. Chin J Cancer. 2013;32:5:242—252. http:// doi. org/10.5732/cjc.012.10263

58.        Fayed YM, Tsibris JC, Langenberg PW, Robertson AL. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest. 1989;60:1:30—37. PMID: 2536127.

59.        Liang ML, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther. 2006;5:1:28—33. http://doi. org/10.4161/cbt.5.1.2234

60.        Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest. 1997;76:2:245—255. PMID: 9042161

61.        Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000;108:SUPPL. 5:795—802. http://doi. org/10.2307/3454309

62.        Sanci M, Cihan D, Sevinc I, Elgin T, Nilgun D, Cigdem I. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem. 2011;113:3:317—325. http://doi. org/10.1016/j. acthis.2010.01.001

63.        Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci. 2001;101:6:691—695. http:// doi. org/10.1042/CS20010096

64.        Hassan MH, Eduardo E, Hossam AMM, Farid HMA, Salama SA, Al-Hendy AI: A novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008;199:2. http:// doi. org/10.1016/j. ajog.2008.02.010

65.        Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson EDB, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006;21:9:2408—2416. https://doi. org/10.1093/humrep/del159

66.        , , Исследование ассоциации полиморфизма 754с/g гена fgfii с развитием миомы матки. Курский научно-практический вестник «Человек и его здоровье». 2013;2:5—8. [Bilichenko M. V., Bushueva O. Yu., Kudryavtseva O. K. Investigation of association of polymorphism 754c / g of fgfii gene with the development of uterine fibroids. Kurskii nauchno-prakticheskii vestnik «Chelovek i ego zdorov'e». 2013;2:5—8. (In Russ.)] УДК: 618.14-006.36: 575.174.015.3

67.        Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth. Biochimie. 2006;88:2:141—146. https://doi. org/10.1016/j. biochi.2005.07.014

68.        Wolanska M. Fibroblast growth factor gene expression in uterine leiomyomas. Ginekol Pol. 79555–9. 2008;79:555—559.

69.        Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod. 1997;3:8:685—691. http://doi. org/10.1093/molehr/3.8.685

70.        Bodner-Adler B, Mayerhofer K, Czerwenka K, Kimberger O, Koelbl H, Bodner K. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study. Eur J Obstet Gynecol Reprod Biol. 2016;207:62—67. http:// doi. org/10.1016/j. ejogrb.2016.10.028

71.        Borahay MA,1,2 Al-Hendy A, Kilic GS, Boehning D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015;21:242—256. http://doi. org/10.2119/molmed.2014.00053

72.        Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, Vale W, Castellucci M. Growth factors and myometrium: Biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17:6:772—790. http://doi. org/10.1093/humupd/dmr031

73.        Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab. 2001;86:2:913—920. https://doi. org/10.1210/jcem.86.2.7237

74.        Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:5:1006—11. https://doi. org/10.1016/S0015-0282(00)00418-0

75.        Salama SA, Diaz-Arrastia CR, Gokhan SK, Kamel MW. 2-Methoxyestradiol causes functional repression of transforming growth factor  signaling by ameliorating Smad and non-Smad signaling pathways in immortalized uterine fibroid cells. Fertil Steril. 2012;98:1:178—184. https://doi. org/10.1016/j. fertnstert.2012.04.002

76.        Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI, Walker CL. Tumor-specific efficacy of transforming growth factor-вRI inhibition in eker rats. Clin Cancer Res. 2007;13:10:3087—3099. http://doi. org/10.1158/1078-0432.CCR-06-1811

Поступила 05.02.18.